U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H22O4
Molecular Weight 302.3649
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MASOPROCOL

SMILES

C[C@@H](CC1=CC=C(O)C(O)=C1)[C@H](C)CC2=CC(O)=C(O)C=C2

InChI

InChIKey=HCZKYJDFEPMADG-TXEJJXNPSA-N
InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+

HIDE SMILES / InChI

Molecular Formula C18H22O4
Molecular Weight 302.3649
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Misoprostol is an antineoplastic drug used to treat skin growths caused by sun exposure. Masoprocol is a novel antineoplastic agent was used for the treatment of actinic keratoses (precancerous skin growths that can become malignant if left untreated). Masoprocol was withdrawn from the U.S. market in June 1996. It is not known exactly how Masoprocol works. Studies have shown that masoprocol is a potent 5-lipoxygenase inhibitor and has antiproliferative activity against keratinocytes in tissue culture, but the relationship between this activity and its effectiveness in actinic keratoses is unknown. Masoprocol also inhibits prostaglandins but the significance of this action is not yet known. Symptoms of overdose or allergic reaction include bluish coloration of skin, dizziness, severe, or feeling faint, wheezing or trouble in breathing.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACTINEX

Cmax

ValueDoseCo-administeredAnalytePopulation
14.7 μg/mL
50 mg/kg single, intravenous
MASOPROCOL plasma
Mus musculus

AUC

ValueDoseCo-administeredAnalytePopulation
247.7 μg × min/mL
50 mg/kg single, intravenous
MASOPROCOL plasma
Mus musculus

T1/2

ValueDoseCo-administeredAnalytePopulation
135 min
50 mg/kg single, intravenous
MASOPROCOL plasma
Mus musculus

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
Apply to lesions b.i.d. for 14–28 d
Route of Administration: Topical
In Vitro Use Guide
Incubation of masoprocol (50 uM) with adipocytes from chow-fed rats significantly inhibited isoproterenol-induced lipolytic activity and HSL activity, associated with a decrease in the ability of isoproterenol to phosphorylate HSL. Masoprocol had no apparent effect on adipose tissue phosphatidylinositol 3-kinase activity, but okadaic acid, a serine/threonine phosphatase inhibitor, blocked the antilipolytic effect of masoprocol.
Substance Class Chemical
Record UNII
7BO8G1BYQU
Record Status Validated (UNII)
Record Version